TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Pre-op NRT on Peri-operative Complications and Long-term Abstinence: A Pilot Trial in Patients Undergoing CABG Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient is currently smoking \>5 cigarettes/day for the past 30 days; there is no evidence that NRT is useful in those who smoke \<5cpd.~2. Patient is able to participate and willing to provide informed consent; participants will need to follow directions and adhere to the medication usage instructions as outlined in the informed consent document.~3. Patients is willing to be contacted by phone for follow up at 1 month and 6 months post-discharge; these time points will assess our final outcome of cessation at 6 months post-discharge.~Exclusion Criteria:~1. Patient is scheduled for surgery in \< 7 days; most patients need to be using NRT consistently for 2 weeks for it to be fully effective.~2. Patient is currently using a smoking cessation product (i.e. nicotine containing patch, gum, inhaler, lozenge, spray or nicotine containing electronic cigarette, varenicline, buproprion) or has used a smoking cessation aid consistently for more than 72 consecutive hours with the intent to reduce cigarette consumption or quit smoking within 30 days of the baseline Pre-admission Unit (PAU) visit; this will ensure the effects of the study patches will be assessed without any contamination from other cessation products.~3. Patient is willing to refrain from using any other cessation products (nicotine containing patch, gum, inhaler, lozenge, spray, nicotine containing electronic cigarette, varenicline, buproprion) prior to surgery; this will allow us to track the usage and side effects with the study patches.~4. Patient is allergic to the adhesive on the nicotine replacement therapy patch.~5. Patient is unable to read and understand English or French; study materials will only be supplied in these two languages.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: NO_INTERVENTION): Participants will receive 3 weeks of inactive NRT patches.
- Active (Type: ACTIVE_COMPARATOR): Participants will receive 3 weeks of active NRT patches

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Mochudi Prevention Project ART Protocol

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 infection~* CD4 cell count ≥ 250 cells/mm3~* HIV-1 RNA ≥ 50,000 cp/mL~* No AIDS-defining illness or other illness that would cause volunteer to be eligible for ART through the Botswana National Program (these volunteers should be referred to the National Program for treatment)~* Age 16 to 64 years~* Botswana citizen~* Resident of the north-east segment of Mochudi~* The following laboratory values obtained within 60 days prior to study enrollment:~  * Absolute neutrophil count (ANC) ≥ 500 cells/mm3.~ * Hemoglobin ≥ 7.0 g/dL.~ * AST (SGOT), ALT (SGPT), and bilirubin ≤ 5 X ULN. Note: if the estimated creatinine clearance (by Cockgroft-Gault equation) is \<60 mL/min, then TDF/FTC will be substituted with ZDV/3TC~* Ability to swallow oral medications.~* Ability and willingness of participant to give informed consent (or in case of participants \< 18 years of age, ability and willingness to provide assent; and for parent/guardian to provide consent).~* Not currently involuntarily incarcerated.~* Karnofsky performance score ≥ 70 at time of study enrollment.~* If participating in sexual activity that could lead to pregnancy and of reproductive potential, female participants must use two reliable methods of contraception simultaneously, one of which must be a barrier method, while receiving protocol-specified medications, and for 12 weeks after stopping the medications.~* For participants \< 18 years of age: Weight of 40kg or more~Exclusion Criteria:~* Receipt at any time prior to study enrollment of \> 7 days cumulative treatment with any ARV or combination of ARVs (except ARVs taken for any length of time during pregnancy for the prevention of mother-to-child transmission (pMTCT) or ARVs taken for occupational exposure).~* Current receipt of 3-drug ART for pMTCT~* Allergy/sensitivity to any study drug or its formulations.~* Acute therapy for serious medical illnesses, in the opinion of the site investigator, within 14 days prior to enrollment.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Nasal Suction in Infants With Bronchiolitis Using a NoseFrida vs. Bulb Syringe

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infants 18 months of age or younger~* Evaluated in the Emergency Center at Beaumont, Royal Oak~* Diagnosis of bronchiolitis, or presenting symptoms that are consistent with this diagnosis, such as cough, difficulty in breathing, wheezing, decreased oral intake, Fever~* Initial Emergency Center visit for the current illness~Exclusion Criteria:~* Clinically ill, as defined by: Requiring respiratory support (ex. O2 nasal canula, or HFNC) or Abnormal respiratory rate on most recent measurement, per Pediatric Advanced Life Support (PALS) guidelines: Infant- \>53 breaths per minute, Toddler- \>37 breaths per minute~* Any history of structural upper airway disease, including Cleft palate, Tracheomalacia/laryngomalacia or Subglottic stenosis~* Previously enrolled in the study

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Months
- Healthy Volunteers: f

Study Arms:
- Nasal suction device: Nose Frida (Type: EXPERIMENTAL): Nose Frida nasal suction device to clear nasal secretions
- Nasal suction device: Bulb (Type: ACTIVE_COMPARATOR): Bulb syringe suction device to clear nasal secretions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Norfloxacin Therapy for Patients With Cirrhosis and Severe Liver Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years,~* Liver failure as defined by a Child-Pugh score ≥ 10 points,~* Accept to participate,~* Have health insurance.~Exclusion Criteria:~* Pregnancy,~* Patient who has been treated with a quinolone in the month before his inclusion~* Allergy to quinolones,~* Hepatocellular carcinoma, and~* HIV infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Norfloxacin (Type: ACTIVE_COMPARATOR): Patients with severe cirrhosis treated with norfloxacin
- Placebo (Type: PLACEBO_COMPARATOR): Patients with severe cirrhosis treated with placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Optimal Sensing in Atrial Tachyarrhythmia's Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with class I or II pacing indications for Sick Sinus Syndrome with suspected paroxysmal atrial tachyarrhythmias over the last 6 months~* Signed informed consent~* Age \>18 yrs~Exclusion Criteria:~* Severe valvular heart disease (echocardiogram less than 6 months old)~* Angina Pectoris class ≥ III~* Congestive heart failure - NYHA class ≥ III~* Left Ventricular Ejection Fraction \< 35% (less than 6 months old)~* Hypertrophic Cardiomyopathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Optisense lead (Type: ACTIVE_COMPARATOR): Patients with an Accent pacemaker and an OptiSense atrial lead
- Tendril lead (Type: ACTIVE_COMPARATOR): Patients with an Accent pacemaker and a Tendril atrial lead

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Hemodynamic Effect of Lumbosacral Plexus Blockade Versus Spinal Anesthesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients for total hip replacement at Aarhus University Hospital~* Age \>= 50 years~* American Society of Anesthesiologists physical status classification score I-III~* Informed consent~Exclusion Criteria:~* Lack of ability to cooperate~* Lack of ability to speak Danish~* Chronic pain, that demands opioid treatment. Not inkl. hip pain.~* Previous venous thromboembolic event~* Previous major back surgery~* Severe cardiopulmonary disease (NYHA class 4)~* Severe untreated hypertension (systolic blood pressure \> 160 mm Hg or diastolic blood pressure \> 110 mm Hg)~* Obesity (BMI \> 35 kg/m\^2)~* Pregnancy~* Allergy towards the used local analgetics~* Current treatment with amiodarone or verapamil

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lumbosacral plexus blockade (Type: EXPERIMENTAL): Peripheral nerve blockade of lumbar and sacral plexus with ropivacaine max 225 mg perineural
- Continuous spinal anesthesia (Type: ACTIVE_COMPARATOR): Continuous spinal anesthesia with plain bupivacaine max 15 mg intrathecal

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Nitazoxanide Plus Atazanavir for COVID-19 Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willingness and ability to provide written informed consent~* At least 18 and not more than 75 years of age at study entry~* SARS-CoV-2 infection confirmed by PCR test within 4 days before randomization~* Currently symptomatic (fever or chills, cough, myalgia, sore throat, shortness of breath, or new onset of anosmia or ageusia) and at COVID-19 isolation and treatment centre~Exclusion Criteria:~* Inability to take orally administered medication or food~* Known hypersensitivity to study medication~* Pregnant or lactating (unless practicing exclusive replacement feeding for the entire study duration)~* Participation in any other interventional trial for COVID-19 (observational study co-enrollment allowed)~* Concurrent treatment with other agents with actual or possible direct-acting antiviral activity against SARS-CoV-2 less than 24 hours prior to study drug dosing~* Concurrent use of agents with known or uncertain interaction with study drugs, including ritonavir~* Requiring mechanical ventilation at screening~* Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) above 5 times upper limit of normal (ULN)~* Creatinine clearance below 50 mL/min using the Cockcroft-Gault formula for participants above 18 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Standard of Care (SOC) (Type: ACTIVE_COMPARATOR): Participants in this arm will receive SOC alone, which will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19
- SOC plus Intervention (Type: EXPERIMENTAL): Participants in this arm will receive SOC plus study intervention composed of orally administered nitazoxanide and atazanavir/ritonavir tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Random-start Ovarian Stimulation in Egg-donors (ROSE)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Premenopausal women~* 18-35 years old~* FSH levels \< 10 IU/liter~* Antral follicle count (AFC) \> 10~* Regular cycles~* Body Mass Index (BMI) \< 28~* Signed informed consent~Exclusion Criteria:~* Polycystic ovary syndrome (PCOS) patients~* Allergy to gonadotrophins~* Concomitant participation in other trial

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Random start ovarian stimulation (Type: EXPERIMENTAL): Egg-donors will be assigned to random start ovarian stimulation: During follicular phase starting at day 5,7,9,11 or 13 of the menstrual cycle and during luteal phase at luteinizing hormone (LH) peak +3,+5,+7,+9 or +11. They will receive urinary follicle stimulating hormone (FSH) 150-225 International units / daily (IU/d) and five days later the gonadotropin-releasing hormone (GnRH) antagonist: cetrorelix acetate 0,25 mg/d will be added until achieving criteria for receiving triptorelin 0,2 mg to induce final follicular maturation. Egg collection will take place 36 hours later.~Interventions:~* Random start ovarian stimulation~* Gonadotrophins: Urinary FSH 150-225 IU/d~* GnRH antagonists: Cetrorelix 0,25 mg/d~* GnRH agonist for triggering: Triptorelin 0,2 mg single dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of acute ischemic stroke~* Informed consent~* Age between 18 and 85 years~* Treatment can be initiated within 3 to 9 hours after the onset of stroke symptoms~* NIHSS Score of 4 to 24~* Vessel occlusion or high-grade stenosis on MRI or CTA in proximal cerebral arteries~Exclusion Criteria:~* Pre-stroke mRS \>1~* Previous exposure to desmoteplase~* Extensive early infarction on MRI or CT in any affected area~* Imaging evidence of ICH or SAH; AV malformation; cerebral aneurysm; or cerebral neoplasm~* Internal carotid artery occlusion on the side of the stroke lesion~* Treatment with heparin in the past 48 hours and a prolonged partial thromboplastin time~* Treatment with oral anticoagulants and a prolonged prothrombin time~* Treatment with glycoprotein IIb - IIIa inhibitors within the past 72 hours. Use of single agent oral platelet inhibitors is permitted~* Treatment with a thrombolytic agent within the past 72 hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Desmoteplase (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Bindex Ultrasonometer for Osteoporosis Diagnostics

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal women and men referred for bone density examination.~Exclusion Criteria:~* Patients unable to sign consent for participation.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Men (Type: None): 140 Men
- Female (Type: None): 500 Female

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Hemodynamic Differentiation of Tachycardia Episodes Using Tissue Perfusion

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Indication for: an electrophysiological study with ventricular stimulation OR the implantation of an implantable cardioverter defibrillator (ICD)~* Patient is at least 18 years old.~* Patient is able and willing to give informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): All Patients underwent Intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: RESILIENCE Trial: Evaluation of the Durability of Aortic Bioprostheses/Valves With RESILIA Tissue in Subjects Under 65

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. 18 years or older~2. Subject currently has an Edwards pericardial aortic bioprosthesis with RESILIA tissue~3. Provides voluntary written informed consent prior to the first trial related procedure~4. Subject agrees to attend follow-up assessments as specified in the protocol~Exclusion Criteria:~1. Age 65 years or older at time of aortic valve replacement~2. The Subject is pregnant or planning to become pregnant at the time of screening~3. Re-intervention required on the bioprosthetic aortic valve prior to screening~4. Active endocarditis or history of endocarditis on bioprosthetic aortic valve~5. Estimated life expectancy \<24 months~6. Subjects with history of or current renal failure requiring dialysis~7. Altered mineral metabolism (hyperparathyroidism, parathyroid tumors)~8. Has prior organ transplant or is currently an organ transplant candidate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Kidney Information Network for Disease Research and Education

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adults between 18 and 65 with ESRD undergoing dialysis.~Exclusion Criteria:~* Kidney biopsy unlikely to be Fabry disease; those with a diagnosis that is clinically or biochemically proven not to be Fabry disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age from 18 to 70~* Patient suffering migraine or probable migraine (diagnosis made by neurologist according to IHCD3)~* Present migraine attack lasting ≤ 72 hours~* Headache intensity moderate or severe on the verbal ordinal scale (4 levels: no headache, mild, moderate or severe)~* Patient requiring parenteral treatment~* Affiliation to the French Health-care System sécurité sociale~Exclusion Criteria:~* abnormalities of neurological exam, seizure, fever (≥ 38°C), and/or SBP≥180 and/or DBP≥110 mmHg~* suspicion of secondary headache~* inability to understand the consent or scales~* pregnancy or breast-feeding~* known respiratory or liver insufficiency~* acute alcohol consumption or alcoholism~* myasthenia~* Patient requiering treatment with sumatriptan SC, particularly in the event of failure of an anti-inflammatory drug at an effective dose taken within 6 hours~* recent use of benzodiazepines (\< 24h diazepam, clonazepam, clorazepate ; \< 6h alprazolam, lorazepam, midazolam)~* recent use of pain killers (\< 2h)~* contraindication to any of the investigational medication~* contraindication to intravenous access~* previous participation to this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Control arm (Type: PLACEBO_COMPARATOR): placebo and standard care :~* Placebo IV~* Ketoprofen 100 mg IV (if nausea-vomiting)~* Metoclopramide 10 mg IV(if nausea-vomiting)
- Experimental arm (Type: EXPERIMENTAL): clorazepate and standard care :~* Clorazepate 20 mg IV~* Ketoprofen 100 mg IV (if nausea-vomiting)~* Metoclopramide 10 mg IV(if nausea-vomiting)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues